您现在位置：健康网-医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告

Osteoporosis Drugs Market Report

健康网讯：

Osteoporosis Drugs Market Report (2007 edition)

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published:  July 2007
Format:  Adobe PDF
Price:  US$ 1,600
Contact: Mr. Bian chenghua   Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101             Fax:  86-10-68052505
E-mail: bianch@healthoo.com   wuhf@healthoo.com   

Table of contents
Summary
About Osteoporosis
About drugs for Osteoporosis
1. Market scale and growth trend of Osteoporosis Drugs from 2002 to 2006
  1.1 Sales value and growth trend of drugs for regulating bone metabolism 2002-2006
  1.2 Market scale of bone mineralization drugs 2002～2006
     1.2.1 Market shares of different breeds of calcium preparations
     1.2.2 Market shares of vitD and it's active metabolites
  1.3 Growth trend of Representative Osteoporosis Drugs from 2002-2006
     1.3.1 Calcitonin class
     1.3.2 Phosphonate class
     1.3.3 Hormone class
2.Sales ananlysis about top breeds or brands
  2.1 Sales rank of breeds and analysis of their respective anvandages 2002～2006
  2.2 Sales rank of brands and analysis of their respective anvandages 2002～2006
  2.3 Sales shares of key enterprises on key breeds
     Calcitonin
     Alendronate Sodium)
     Elcitonin
     Disodium Clodronate
     Etidronate Disodium
     Raloxifene
     Ipriflavone
  2.4 Retail prices of key breeds
3 Sales statistics of key brands in key cities
    "Miacalcic"
    "FuShanMei"
    "YiGaiNing"
    "GuBang"
    "GuLing"
    "BangRuiDe"
    "YiWeiTe"
    "Bangtelin"
4 Sales share of different brands in key cities
  Shanghai
  Beijing
  Guangzhou
5 Research and development in China
  5.1 List of Domestic marketd products and import procucts
  5.2 Status of application and approval

Tables and figures
Table 1 Classification of drugs for Osteoporosis
Table 2 Market scale of Osteoporosis drugs in whole nation 2002~2006
Table 3 Market scale of bone mineralization drugs 2002～2006
Table 4 Sales values of respective calcium preparations 2002～2006
Table 5 Sales values of vitD and it's active metabolite products 2002～2006
Table 6 Sales values of five sorts of osteoporosis drugs 2002～2006
Table 7 Sales values of Calcitonin class 2002～2006
Table 8 Sales values of Phosphonate class 2002～2006
Table 9 Sales values of Hormone class 2002～2006
Table 10 Sales values of representative osteoporosis drugs 2002～2006
Table 11 Sales values of key brands 2002～2006
Table 12 Market shares of key brands 2002～2006
Table 13 Market shares of representative brands in 2006
Table 14 Sales values of Calcitonin class for different enterprises 2002~2006
Table 15 Sales values of Alendronate Sodium for different enterprises 2002~2006
Table 16 Sales values of Elcitonin for different enterprises 2002~2006
Table 17 Sales values of Disodium Clodronate for different enterprises 2002~2006
Table 18 Sales values of Etidronate Disodium for different enterprises 2002~2006
Table 19 Enterprise list which is applying for Raloxifene to SFDA
Table 20 Retail prices of key osteoporosis drugs
Table 21 Retail prices of key osteoporosis drugs 2002~2006
Table 22 Market share of FuShanMei (Alendronate) in key cities 2002~2006
Table 23 Market share of YiGaiNing (Elcitonin) in key cities 2002~2006
Table 24 Market share of YiGaiNing (Elcitonin) in key cities 2002~2006
Table 25 Market share of GuLing in key cities 2002~2006
Table 26 Market share of GuLing in key cities 2002~2006
Table 27 Market share of YiWeiTe (Raloxifene) in key cities 2002~2006
Table 28 Market share of Bangtelin (Etidronate Disodium) in key cities 2002~2006
Table 29 Region shares of osteoporosis drugs 2002~2006
Table 30 Market shares of different osteoporosis drugs in Shanghai 2002~2006
Table 31 Market shares of different brands in Shanghai 2006
Table 32 Market shares of different osteoporosis drugs in Beijing 2002~2006
Table 33 Market shares of different brands in Beijing 2006
Table 34 Market shares of different osteoporosis drugs in Guangzhou 2002~2006
Table 35 Market shares of different brands in Guangzhou 2006

Table 36 to talbe 41 is about the infromation of registration and approval for osteoporosis drugs
There are 16 figures.